Company Overview of PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs that focus on endocrine and metabolic disorders, and cardiovascular diseases. Its development candidates include PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and changed its name to PhaseBio Pharmaceuticals, Inc. in November 2008. The company was founded in 2002 and is based in Malvern, Pennsylvania.
One Great Valley Parkway
Malvern, PA 19355
Founded in 2002
Key Executives for PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Tensha Therapeutics, Inc.||United States|
|Matrixx Initiatives, Inc.||United States|
|Nuovo Biologics, L.L.C.||United States|
|ARIAD Gene Therapeutics, Inc.||United States|
|MiniVax, Inc.||United States|
Recent Private Companies Transactions
February 26, 2015
To contact PhaseBio Pharmaceuticals, Inc., please visit www.phasebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.